Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Share-based Compensation (2016 - 2025)

Lineage Cell Therapeutics' Share-based Compensation history spans 16 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 16.5% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $4.8 million, down 6.4%, while the annual FY2025 figure was $4.8 million, 6.4% down from the prior year.
  • Share-based Compensation reached $1.1 million in Q4 2025 per LCTX's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.3 million in Q3 2024 to a low of $102000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $1.1 million, with a median of $1.2 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: crashed 83.71% in 2021, then surged 984.31% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $918000.0 in 2021, then increased by 4.47% to $959000.0 in 2022, then grew by 10.53% to $1.1 million in 2023, then grew by 24.06% to $1.3 million in 2024, then fell by 16.5% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Share-based Compensation are $1.1 million (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025).